FASLG and lymphoma: Humans with defective Fas/Fas ligand (FasL) signaling develop autoimmune lymphoproliferative syndrome (ALPS)23, 24, 25, whose main characteristics are DN T cell accumulation and lymphadenopathy development, propensity to lupus autoimmunity, and increased risk for lymphoma.